K2 Principal Fund, L.P. Pharma Cyte Biotech, Inc. Call Options Transaction History
K2 Principal Fund, L.P.
- $285 Million
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding PMCB
# of Institutions
32Shares Held
1.07MCall Options Held
5.4KPut Options Held
400-
Geode Capital Management, LLC Boston, MA200KShares$412,5780.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA175KShares$359,6800.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$189,6997.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$170,4170.12% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny43.8KShares$90,2280.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $42.7M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...